217 related articles for article (PubMed ID: 27986684)
1. MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.
Cranston RD; Lama JR; Richardson BA; Carballo-Diéguez A; Kunjara Na Ayudhya RP; Liu K; Patterson KB; Leu CS; Galaska B; Jacobson CE; Parikh UM; Marzinke MA; Hendrix CW; Johnson S; Piper JM; Grossman C; Ho KS; Lucas J; Pickett J; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu AY; Mayer KH; Zorrilla C; Schwartz JL; Rooney J; McGowan I;
Clin Infect Dis; 2017 Mar; 64(5):614-620. PubMed ID: 27986684
[TBL] [Abstract][Full Text] [Related]
2. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
3. An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.
McGowan IM; Kunjara Na Ayudhya RP; Brand RM; Marzinke MA; Hendrix CW; Johnson S; Piper J; Holtz TH; Curlin ME; Chitwarakorn A; Raengsakulrach B; Doncel G; Schwartz JL; Rooney JF; Cranston RD
AIDS Res Hum Retroviruses; 2022 Apr; 38(4):279-287. PubMed ID: 34541872
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
[TBL] [Abstract][Full Text] [Related]
5. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
[TBL] [Abstract][Full Text] [Related]
6. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
7. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
9. Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.
McGowan I; Cranston RD; Mayer KH; Febo I; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Park SY; Brand RM; Jacobson C; Giguere R; Dolezal C; Frasca T; Leu CS; Schwartz JL; Carballo-Diéguez A
PLoS One; 2016; 11(6):e0158310. PubMed ID: 27362788
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
13. Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study.
Richardson-Harman N; Hendrix CW; Bumpus NN; Mauck C; Cranston RD; Yang K; Elliott J; Tanner K; McGowan I; Kashuba A; Anton PA
PLoS One; 2014; 9(10):e111507. PubMed ID: 25350130
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
16. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
McGowan I; Hoesley C; Cranston RD; Andrew P; Janocko L; Dai JY; Carballo-Dieguez A; Ayudhya RK; Piper J; Hladik F; Mayer K
PLoS One; 2013; 8(4):e60147. PubMed ID: 23573238
[TBL] [Abstract][Full Text] [Related]
18. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Orkin C; Squires KE; Molina JM; Sax PE; Wong WW; Sussmann O; Kaplan R; Lupinacci L; Rodgers A; Xu X; Lin G; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C; Martin EA;
Clin Infect Dis; 2019 Feb; 68(4):535-544. PubMed ID: 30184165
[TBL] [Abstract][Full Text] [Related]
19. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
